CD45RA-depleted T-memory cells for infection prevention post-HSCT

Phase 3, randomised, open-label trial of CD45RA depleted donor lymphocyte infusion in cytomegalovirus infection (CMV) (2 arms), sponsored by Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Primary endpoints: Cumulative incidence of the probability of CMV-reactivation at 120 days and Cumulative incidence of acute GVHD grade II-IV at 150 days. Started Oct 2016; status: completed.